A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00355524
Recruitment Status : Completed
First Posted : July 24, 2006
Last Update Posted : July 8, 2013
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland